Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
View/ Open
Date
2016-05ICR Author
Author
Bowyer, S
Prithviraj, P
Lorigan, P
Larkin, J
McArthur, G
Atkinson, V
Millward, M
Khou, M
Diem, S
Ramanujam, S
Kong, B
Liniker, E
Guminski, A
Parente, P
Andrews, MC
Parakh, S
Cebon, J
Long, GV
Carlino, MS
Klein, O
Type
Journal Article
Metadata
Show full item recordAbstract
Background Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.Methods We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg(-1) for a maximum of four doses.Results Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient.Conclusions Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.
Collections
Subject
Humans
Melanoma
Skin Neoplasms
Neoplasm Metastasis
Antineoplastic Agents
Antibodies, Monoclonal
Treatment Outcome
Drug Administration Schedule
Retrospective Studies
Adult
Aged
Middle Aged
Female
Male
Ipilimumab
Research team
Melanoma and Kidney Cancer
Language
eng
Date accepted
2016-03-14
License start date
2016-05
Citation
British journal of cancer, 2016, 114 (10), pp. 1084 - 1089